Statistical analysis
AML
The sample size calculation for the trial was based on the assumption that the VAH regimen would achieve a higher CRc rate compared with historical CRc rate of 45% (on the basis of venetoclax in combination with HMAs study by our previous and others in R/R AML) [The clinical data cutoff date was June 30, 2022. The descriptive analysis of patient characteristics included median and interquartile range (IQR) for continuous variables, and absolute and relative frequencies for categorical variables. The time-to-event endpoints including OS, EFS and DFS were analyzed by the Kaplan–Meier method and compared using the log-rank tests. The corresponding hazard ratio (HR) and 95% CI were estimated using the Cox proportional hazards model. The cumulative incidences of relapse were calculated by accounting for competing risks, and non-relapse mortality was a competing risk for relapse. The comparison of the cumulative incidence in the presence of a competing risk was done using the Fine and Gray model [